Rituximab offered little therapeutic benefit in Graves' ophthalmopathy Healio SAN JUAN, Puerto Rico — In a randomized, double blind, placebo-controlled trial, rituximab did not effect significant clinical improvement in Graves' ophthalmopathy and had a 50% success/failure rate in patients with the disease. “In patients with ... |
